<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563654</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2005.332</org_study_id>
    <secondary_id>HARECCTR0500048</secondary_id>
    <nct_id>NCT00563654</nct_id>
  </id_info>
  <brief_title>Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up</brief_title>
  <official_title>Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo on the Successful Rate of Trial Without Catheter in Patients With Acute Urinary Retention With Long Term Follow up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare alfuzosin GITS once daily versus placebo in achieving
      a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in delaying or
      avoiding a TURP.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful rate of Trial Without Catheter (TWOC) at phase 1</measure>
    <time_frame>At discharge after TWOC (at the end phase one)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Late failure of TWOC of, which is defined as recurrent of AUR or the need of invasive therapy among those who are successful in TWOC in phase 1</measure>
    <time_frame>From the end of phase one to eight months after successful TWOC (the end of phase 2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with hypotension or symptoms related to hypotension after administration of treatment drug for TWOC</measure>
    <time_frame>From the time of treatment drug administration to the end of phase 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak flow rate (Qmax), voided volume (Vcomp) and post-voided residue volume (PVR)</measure>
    <time_frame>At the end of phase I (discharge after TWOC) and at the end of phase 2</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <condition>Urinary Retention</condition>
  <condition>Acute Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfuzosin GITS (Xatral XL)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 50 or above

          -  Admitted for AUR due to BPH with PVR of 500 ml or more

        Exclusion Criteria:

          -  Previous history of TURP

          -  Use of alpha blockers within recent 8 months

          -  Renal impairment (serum creatinine &gt;140 umol/l)

          -  Poor premorbid state
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Chi Wai Cheng, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Division of Urology, North District Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North District Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>June 15, 2011</last_update_submitted>
  <last_update_submitted_qc>June 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2011</last_update_posted>
  <keyword>Benign Prostatic Hyperplasia (BPH)</keyword>
  <keyword>Acute Retention of Urine (AUR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Urinary Retention</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

